Annual General Meeting 2013 19 November 2013

Ross Dobinson Executive Chairman

1

Forward Looking Statements Certain statements in this presentation relate to the future, including forward looking statements and worked examples relating to Hexima’s future expectations, beliefs, goals, plans, prospects, financial position and strategy. These forward looking statements and worked examples involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual results, performance or achievements of Hexima to be materially different from future results, performance or achievements expressed or implied by such statements or examples. Neither Hexima nor any other person gives any representation, assurance or guarantee that the occurrence expressed or implied in any forward looking statements or worked examples in this document will actually occur and you are cautioned not to rely on such forward looking statements or worked examples.

Subject to any continuing obligations under applicable law, Hexima disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements or worked examples in this document to reflect any change in expectations in relation thereto or any change in events, conditions or circumstances on which any such statement or example is based.

This presentation is an overview of Hexima and does not purport to be all inclusive or contain all information which its recipients may require in order to make an informed assessment of Hexima’s prospects. Recipients should make their own independent assessment and investigation in respect of any investment decisions and should not rely on any statement contained in this presentation.

2

Cash Position Stabilised 2007 2011 2013 2015f’cast

Cash $40m $15.3m $10m $7m

Burn rate/pa $5-6m $7.3m $2.4m Cash neutral

Focus (time to market)

Insect control (13 y)

Fungal disease (13 y)

Insects (10 y)

Disease (10 y)

Systemic cancer (15 y)

Insects (8 y)

Disease (8 y)

Cancer (3 y)

Human antifungals (3 y)

Insects (6 y)

Disease (6 y)

Cancer (1 y)

Human antifungals (1 y)

Contract field work

Resources LaTrobe & Melb. Uni. Labs

LaTrobe glasshouses

LaTrobe & Melb. Uni. Labs

LaTrobe glasshouses

City office

LaTrobe labs

LaTrobe glasshouses

City office

Further consolidation

3

!   Hexima has been managing Canola field trials in Australia on behalf of DuPont-Pioneer for 2 years and is likely to do so for a further 2 years

Fee for service

4

!   Hexima has been approached to provide laboratory research services, glasshouse facilities and field trial support for a 4 year field trial with another company −  This is a highly complementary

business for Hexima as it leverages existing resources with relatively low marginal cost

−  The potential exists to expand contract service operations which will generate additional cash flow for the Company and reduce our overall burn rate

Fee for service

5

!   Hexima is negotiating a funded discovery program for novel insecticidal genes for production of GM crops that are resistant to insect damage

!   The 2012 global market for insect resistant GM plants was worth US$6.5bn, or 43% of the GM seed and trait market

!   Work is expected to commence on the program in Q1 2014. Hexima will be entitled to royalties from all novel insecticidal genes that are discovered during the program and commercialised

!   The program is expected to leverage the value of Hexima’s MGEV technology

Insects

Images taken from: https://www.pioneer.com/home/site/us/agronomy/crop-management/corn-insect-

disease/corn-earworm/ and http://www.monsanto.com/products/Pages/research-development-pipeline.aspx

6

Annual General Meeting 2013 19 November 2013

Dr Nicole van der Weerden Head of Technology Commercialization

7

Aim:

To produce transgenic plants (corn, soy, wheat) with broad spectrum resistance to fungal pathogens

2012 corn market:

Conservatively valued at US$48bn in the US.

Disease caused US$6bn in crop loss in the US.

Disease causes losses of >US$80bn annually in global food crops.

Worked Example: Potential Disease Control Trait US Corn Corn Price $4.5 / bu Av Yield 380 bu / Ha Value /Ha $1,710 / Ha ******** Disease Loss 10 -12% % Disease Controlled by Trait 50% - 70% Trait Yield Gain ~5% - 8.4% Trait Yield Gain ~19 - 32 bu / Ha Trait Value ~$85.5 - $144 / Ha ******* Cost Charged to Farmer (40% of trait value) $34.2 - $57.5 / Ha

******* Hexima Royalty (15%) $5.1 - $8.6 / Ha Hexima Royalty (30%) $10.3 - $17.2 / Ha ******* US Market Size 32m Ha ******

Potential Peak Royalties 50%-70% disease reduction 30% market share ~$98m - $166m pa 50% market share ~$164m - $276m pa Note: corn price, disease load, % disease controlled, trait market share and royalties are all assumptions for calculation purposes, not forecasts

Disease resistance – GM crops

8

Progress:

Corn !   Achieved over 70% reduction in

disease severity against 2 major fungal pathogens in glasshouse bioassays with transgenic corn

!   DuPont Pioneer will commence field testing in 2014

!   Exclusivity period for the DuPont Pioneer agreement has ended (August 6th). Negotiations are continuing to extend the partnership and exclusivity period.

Disease resistance – GM crops

Corn pic

9

Progress:

Soy !   Transgenic plants with our lead antifungal

genes are in glasshouse trials in the USA

!   Improved genes from the corn program will be assessed in soy in 2014

Wheat !   Monsanto is testing two Hexima antifungal

genes in wheat

Disease resistance – GM crops

Images taken from: https://www.pioneer.com/home/site/mobile/grow/soybeans/sudden-death-syndrome/ and http://grains.agric.wa.gov.au/category/rainfall/all?page=29 10

Aim: !   To develop novel therapeutics for fungal infections of skin and nails

using proprietary fungicidal molecules developed by Hexima Limited

Antifungal Market: !   The market for human antifungal therapies was valued at

$10.2 billion in 2008 !   Of this $10.2 billion, $7.8 billion were over-the-counter (OTC) sales

and $4 billion was for topically applied products !   Fungal nail infections affect 20-25% of the population and >50% of

people over 70 years of age !   Current therapies for fungal nail infections are ineffective and require

long treatment regimes - many have associated liver toxicity

Human Antifungal Therapeutics

11

Progress: !   Lead compounds are active against the pathogens that cause fungal

skin and nail infections !   A collaboration agreement is in place with Acrux to combine Hexima’s

molecules with Acrux’s delivery technology !   We are developing formulations to deliver the active molecules

through infected nails !   Proof of concept data expected Q1 2014 !   If positive, funding will be required for the joint commercial

development

Human Antifungal Therapeutics

12

Annual General Meeting 2013 19 November 2013

Dr Mark Hulett

13

Aim: !   To develop novel therapeutics for non-melanoma skin cancers (NMSC)

using proprietary anti-cancer molecules developed by Hexima Limited

NMSC Market: !   The total number of NMSC treatments in Australia increased from

412,000 in 1997 to 767,000 in 2010. !   In 2015 NMSC will be the most costly cancer in Australia, with 938,000

treatments expected. The diagnosis, treatment and pathology costs are estimated to be $700 million in 2015

!   The incidence of NMSC is expected to increase substantially in all developed countries

Cancer Therapeutics

14

Progress: !   A collaboration agreement is in place with Acrux Limited to combine

Hexima’s lead molecules with Acrux’s transdermal delivery technology !   A collaborative relationship has been established with leading

Melbourne based medical and research institutions ─  human skin samples that contain NMSC lesions are being

collected ─  we are developing formulations to deliver the active molecules to

cancer cells in the skin ─  preliminary results are promising

Cancer Therapeutics

15

Progress: !   Proof of concept data expected Q4 2013 !   If positive, funding will be required for the joint commercial

development

Cancer Therapeutics

16